Search

Your search keyword '"Bruchim I"' showing total 199 results
Start Over Author "Bruchim I"
199 results on '"Bruchim I"'

1. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Author

Monk, B.J., Barretina-Ginesta, M.P., Pothuri, B., Vergote, I., Graybill, W., Mirza, M.R., McCormick, C.C., Lorusso, D., Moore, R.G., Freyer, G., O’Cearbhaill, R.E., Heitz, F., O’Malley, D.M., Redondo, A., Shahin, M.S., Vulsteke, C., Bradley, W.H., Haslund, C.A., Chase, D.M., Pisano, C., Holman, L.L., Pérez, M. J. Rubio, DiSilvestro, P., Gaba, L., Herzog, T.J., Bruchim, I., Compton, N., Shtessel, L., Malinowska, I.A., and González-Martín, A.

Published
2024
Full Text
View/download PDF

2. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Author

Vergote, I., Ausems, M., Brasiuniene, B., Brenton, J., Büttner, R., Colombo, N., González-Martín, A., Harter, P., Lambrechts, D., Lorusso, D., Madry, R., Mirza, M.R., Pujol, P., Ray-Coquard, I., Abreu, M., Balboni, S., Banerjee, S., Barberis, M., Barretina Ginesta, M.P., Baurain, J.-F., Bignami, M., Bjorge, L., Blecharz, P., Bruchim, I., Capilna, M., Cerana, N., Cicchetti, A., Collins, D., Concin, N., D’Incalci, M., Davidson, B., de la Motte Rouge, T., De Iaco, P., Demirkiran, F., Denys, H., Doerk, T., Dorum, A., Ferrero, A., Fidalgo, A.P., Genuardi, M., Gladieff, L., Glasspool, R., Grimm, C., Gultekin, M., Hahnen, E., Hasenburg, A., Hegmane, A., Heinzelmann, V., Hogdall, E., Janavicius, R., Jarmalaite, S., Kalachand, R., Kaneva, R., Kilickap, S., Kocian, R., Kolencik, D., Kristeleit, R., Kryzhanivska, A., Leary, A., Lemley, B., Ligtenberg, M., López-Guerrero, J.A., Lord, C.J., Avall-Lundqvist, E., Maenpaa, J., Mahner, S., Marmé, F., Marth, C., McNeish, I., Merkelbach-Bruse, S., Mourits, M., Normanno, N., Oaknin, A., Ojamaa, K., Papdimitriou, C., Penault-Llorca, F., Perrone, A.M., Pignata, S., Pikarsky, E., Rouleau, E., Rubio, M., Sapino, A., Schmalfeldt, B., Sehouli, J., Shapira, R., Steffensen, K.D., Sukhin, V., Syrios, J., Szallasi, Z., Taskiran, C., Terzic, M., Tischkowitz, M., Toth, I., Van de Vijver, K., Vardar, M.A., Wasag, B., Wimberger, P., Witteveen, E., Brenton, J.D., and Ausems, M.G.E.M.

Published
2022
Full Text
View/download PDF

3. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere

Author

Bruchim, I., Capasso, Ilaria, Polonsky, A., Meisel, S., Salutari, V., Werner, H., Lorusso, D., Scambia, Giovanni, Fanfani, Francesco, Capasso I., Scambia G. (ORCID:0000-0003-2758-1063), Fanfani F. (ORCID:0000-0003-1991-7284), Bruchim, I., Capasso, Ilaria, Polonsky, A., Meisel, S., Salutari, V., Werner, H., Lorusso, D., Scambia, Giovanni, Fanfani, Francesco, Capasso I., Scambia G. (ORCID:0000-0003-2758-1063), and Fanfani F. (ORCID:0000-0003-1991-7284)

Abstract

Introduction: Endometrial cancer (EC) is the only gynecologic malignancy showing increasing trends in incidence and mortality. While standard treatment has been effective primarily for early-stage EC, precision medicine with tailored therapy has revolutionized the management of this disease. Genome sequencing analyses have identified four sub-types of EC. Treatments for primary and metastatic disease can now be tailored more accurately to achieve better oncologic results. Areas covered: This review provides an overview of the most relevant and updated evidence in the literature regarding EC molecular analysis and its role in risk classification, prognostication, and guidance for tailored and target therapies in early and advanced/metastatic stages. In addition, it provides updated information on optimal surgical management based on molecular classification and highlights key advances and future strategies. Expert opinion: EC molecular analysis yields the potential of tailoring adjuvant treatment by escalating or deescalating therapy, as shown for POLE-mutated and p53-mutated tumors. Moreover, the expression of specific molecular signatures offers the possibility to employ novel target therapies, such as immune-checkpoint inhibitors that have demonstrated a significant benefit on prognosis. New treatment guidelines are still being established, and ongoing studies are exploring the potential prognostic role of further sub-stratifications of the four molecular classes and treatment options.

Published
2024

4. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Author

Baert, T., Banerjee, S., Belaroussi, I., Blecharz, P., Bruchim, I., Cibula, D., Colombo, N., Concin, N., Davidson, B., Dashora, A., Devouassoux-Shisheboran, M., du Bois, A., Ferrero, A., Glasspool, R., González-Martin, A., Heinzelmann-Schwarz, V., Joly, F., Kim, J.W., Kridelka, F., Ledermann, J., Lorusso, D., Mahner, S., McCluggage, W.G., McNeish, I., Mikami, M., Mirza, M.R., Morice, P., Nicum, S., Olbrecht, S., O’Donnell, D.M., Pautier, P., Planchamp, F., Pignata, S., Querleu, D., Ray-Coquard, I., Rodolakis, A., Sehouli, J., Selcukbiricik, F., Sessa, C., Singh, N., Tan, D.S.P., Timmerman, D., Tognon, G., van der Velden, J., Vergote, I., Witteveen, P.O., and Zeimet, A.G.

Published
2019
Full Text
View/download PDF

5. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Author

Vergote, I, Gonzalez-Martin, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M, Brasiuniene, B, Madry, R, Brenton, J, Ausems, M, Buttner, R, Lambrechts, D, Abreu, M, Balboni, S, Banerjee, S, Barberis, M, Barretina Ginesta, M, Baurain, J, Bignami, M, Bjorge, L, Blecharz, P, Bruchim, I, Capilna, M, Cerana, N, Cicchetti, A, Collins, D, Concin, N, D'Incalci, M, Davidson, B, de la Motte Rouge, T, De Iaco, P, Demirkiran, F, Denys, H, Doerk, T, Dorum, A, Ferrero, A, Fidalgo, A, Genuardi, M, Gladieff, L, Glasspool, R, Grimm, C, Gultekin, M, Hahnen, E, Hasenburg, A, Hegmane, A, Heinzelmann, V, Hogdall, E, Janavicius, R, Jarmalaite, S, Kalachand, R, Kaneva, R, Kilickap, S, Kocian, R, Kolencik, D, Kristeleit, R, Kryzhanivska, A, Leary, A, Lemley, B, Ligtenberg, M, Lopez-Guerrero, J, Lord, C, Avall-Lundqvist, E, Maenpaa, J, Mahner, S, Marme, F, Marth, C, Mcneish, I, Merkelbach-Bruse, S, Mourits, M, Normanno, N, Oaknin, A, Ojamaa, K, Papdimitriou, C, Penault-Llorca, F, Perrone, A, Pignata, S, Pikarsky, E, Rouleau, E, Rubio, M, Sapino, A, Schmalfeldt, B, Sehouli, J, Shapira, R, Steffensen, K, Sukhin, V, Syrios, J, Szallasi, Z, Taskiran, C, Terzic, M, Tischkowitz, M, Toth, I, Van de Vijver, K, Vardar, M, Wasag, B, Wimberger, P, Witteveen, E, Vergote I., Gonzalez-Martin A., Ray-Coquard I., Harter P., Colombo N., Pujol P., Lorusso D., Mirza M. R., Brasiuniene B., Madry R., Brenton J. D., Ausems M. G. E. M., Buttner R., Lambrechts D., Ausems M., Brenton J., Abreu M., Balboni S., Banerjee S., Barberis M., Barretina Ginesta M. P., Baurain J. -F., Bignami M., Bjorge L., Blecharz P., Bruchim I., Capilna M., Cerana N., Cicchetti A., Collins D., Concin N., D'Incalci M., Davidson B., de la Motte Rouge T., De Iaco P., Demirkiran F., Denys H., Doerk T., Dorum A., Ferrero A., Fidalgo A. P., Genuardi M., Gladieff L., Glasspool R., Grimm C., Gultekin M., Hahnen E., Hasenburg A., Hegmane A., Heinzelmann V., Hogdall E., Janavicius R., Jarmalaite S., Kalachand R., Kaneva R., Kilickap S., Kocian R., Kolencik D., Kristeleit R., Kryzhanivska A., Leary A., Lemley B., Ligtenberg M., Lopez-Guerrero J. A., Lord C. J., Avall-Lundqvist E., Maenpaa J., Mahner S., Marme F., Marth C., McNeish I., Merkelbach-Bruse S., Mourits M., Normanno N., Oaknin A., Ojamaa K., Papdimitriou C., Penault-Llorca F., Perrone A. M., Pignata S., Pikarsky E., Rouleau E., Rubio M., Sapino A., Schmalfeldt B., Sehouli J., Shapira R., Steffensen K. D., Sukhin V., Syrios J., Szallasi Z., Taskiran C., Terzic M., Tischkowitz M., Toth I., Van de Vijver K., Vardar M. A., Wasag B., Wimberger P., Witteveen E., Vergote, I, Gonzalez-Martin, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M, Brasiuniene, B, Madry, R, Brenton, J, Ausems, M, Buttner, R, Lambrechts, D, Abreu, M, Balboni, S, Banerjee, S, Barberis, M, Barretina Ginesta, M, Baurain, J, Bignami, M, Bjorge, L, Blecharz, P, Bruchim, I, Capilna, M, Cerana, N, Cicchetti, A, Collins, D, Concin, N, D'Incalci, M, Davidson, B, de la Motte Rouge, T, De Iaco, P, Demirkiran, F, Denys, H, Doerk, T, Dorum, A, Ferrero, A, Fidalgo, A, Genuardi, M, Gladieff, L, Glasspool, R, Grimm, C, Gultekin, M, Hahnen, E, Hasenburg, A, Hegmane, A, Heinzelmann, V, Hogdall, E, Janavicius, R, Jarmalaite, S, Kalachand, R, Kaneva, R, Kilickap, S, Kocian, R, Kolencik, D, Kristeleit, R, Kryzhanivska, A, Leary, A, Lemley, B, Ligtenberg, M, Lopez-Guerrero, J, Lord, C, Avall-Lundqvist, E, Maenpaa, J, Mahner, S, Marme, F, Marth, C, Mcneish, I, Merkelbach-Bruse, S, Mourits, M, Normanno, N, Oaknin, A, Ojamaa, K, Papdimitriou, C, Penault-Llorca, F, Perrone, A, Pignata, S, Pikarsky, E, Rouleau, E, Rubio, M, Sapino, A, Schmalfeldt, B, Sehouli, J, Shapira, R, Steffensen, K, Sukhin, V, Syrios, J, Szallasi, Z, Taskiran, C, Terzic, M, Tischkowitz, M, Toth, I, Van de Vijver, K, Vardar, M, Wasag, B, Wimberger, P, Witteveen, E, Vergote I., Gonzalez-Martin A., Ray-Coquard I., Harter P., Colombo N., Pujol P., Lorusso D., Mirza M. R., Brasiuniene B., Madry R., Brenton J. D., Ausems M. G. E. M., Buttner R., Lambrechts D., Ausems M., Brenton J., Abreu M., Balboni S., Banerjee S., Barberis M., Barretina Ginesta M. P., Baurain J. -F., Bignami M., Bjorge L., Blecharz P., Bruchim I., Capilna M., Cerana N., Cicchetti A., Collins D., Concin N., D'Incalci M., Davidson B., de la Motte Rouge T., De Iaco P., Demirkiran F., Denys H., Doerk T., Dorum A., Ferrero A., Fidalgo A. P., Genuardi M., Gladieff L., Glasspool R., Grimm C., Gultekin M., Hahnen E., Hasenburg A., Hegmane A., Heinzelmann V., Hogdall E., Janavicius R., Jarmalaite S., Kalachand R., Kaneva R., Kilickap S., Kocian R., Kolencik D., Kristeleit R., Kryzhanivska A., Leary A., Lemley B., Ligtenberg M., Lopez-Guerrero J. A., Lord C. J., Avall-Lundqvist E., Maenpaa J., Mahner S., Marme F., Marth C., McNeish I., Merkelbach-Bruse S., Mourits M., Normanno N., Oaknin A., Ojamaa K., Papdimitriou C., Penault-Llorca F., Perrone A. M., Pignata S., Pikarsky E., Rouleau E., Rubio M., Sapino A., Schmalfeldt B., Sehouli J., Shapira R., Steffensen K. D., Sukhin V., Syrios J., Szallasi Z., Taskiran C., Terzic M., Tischkowitz M., Toth I., Van de Vijver K., Vardar M. A., Wasag B., Wimberger P., and Witteveen E.

Abstract

Background: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition. Design: To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts’ consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results: A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive. Conclusion: These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR de

Published
2022

13. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)

Author

Monk, B.J., Oaknin, A., O'Malley, D.M., Wilson, M., Lorusso, D., Westin, S., Oza, A.M., Zagouri, F., Herzog, T.J., Mikheeva, O., Parkinson, C., Coleman, R.L., Lim, M.C., Chudecka-Glaz, A.M., Eskander, R.N., Bruchim, I., Ghamande, S., Despain, D., Fujiwara, K., and Kristeleit, R.

Published
2024
Full Text
View/download PDF

14. LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012

Author

González-Martín, A., Pothuri, B., Barretina Ginesta, M.P., Graybill, W.S., Vergote, I.B., McCormick, C., Mirza, M.R., Moore, R.G., Lorusso, D., O'Cearbhaill, R.E., Freyer, G., O'Malley, D.M., Heitz, F., Shahin, M.S., Bruchim, I., Bradley, W.H., Compton, N., Malinowska, I., Redondo, A., and Monk, B.J.

Published
2024
Full Text
View/download PDF

15. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Poveda, A, Floquet, A, Ledermann, J, Asher, R, Penson, R, Oza, A, Korach, J, Huzarski, T, Pignata, S, Friedlander, M, Baldoni, A, Park-Simon, T, Tamura, K, Sonke, G, Lisyanskaya, A, Kim, J, Filho, E, Milenkova, T, Lowe, E, Rowe, P, Vergote, I, Pujade-Lauraine, E, Byrski, T, Pautier, P, Harter, P, Colombo, N, Scambia, G, Nicoletto, M, Nussey, F, Clamp, A, Poveda Velasco, A, Rodrigues, M, Lotz, J, Selle, F, Ray-Coquard, I, Provencher, D, Prat Aparicio, A, Vidal Boixader, L, Scott, C, Yunokawa, M, Medioni, J, Pecuchet, N, Dubot, C, De La Motte Rouge, T, Kaminsky, M, Weber, B, Lortholary, A, Parkinson, C, Williams, S, Banerjee, S, Cosin, J, Hoffman, J, Plante, M, Covens, A, Joly, F, Hirte, H, Amit, A, Matsumoto, K, Tjulandin, S, Hoon Kim, J, Gladieff, L, Sabbatini, R, O'Malley, D, Timmins, P, Kredentser, D, Lainez Milagro, N, Barretina Ginesta, M, Tibau Martorell, A, Gomez De Liano Lista, A, Ojeda Gonzalez, B, Mileshkin, L, Mandai, M, Boere, I, Ottevanger, P, Nam, J, Hamizi, S, Cognetti, F, Warshal, D, Dickson-Michelson, E, Kamelle, S, Mckenzie, N, Rodriguez, G, Armstrong, D, Chalas, E, Celano, P, Behbakht, K, Davidson, S, Welch, S, Helpman, L, Fishman, A, Bruchim, I, Sikorska, M, Slowinska, A, Rogowski, W, Bidzinski, M, Spiewankiewicz, B, Casado Herraez, A, Mendiola Fernandez, C, Gropp-Meier, M, Saito, T, Takehara, K, Enomoto, T, Watari, H, Choi, C, Kim, B, Weon Kim, J, Hegg, R, Poveda A., Floquet A., Ledermann J. A., Asher R., Penson R. T., Oza A. M., Korach J., Huzarski T., Pignata S., Friedlander M., Baldoni A., Park-Simon T. -W., Tamura K., Sonke G. S., Lisyanskaya A., Kim J. -H., Filho E. A., Milenkova T., Lowe E. S., Rowe P., Vergote I., Pujade-Lauraine E., Byrski T., Pautier P., Harter P., Colombo N., Scambia G., Nicoletto M., Nussey F., Clamp A., Penson R., Poveda Velasco A., Rodrigues M., Lotz J. -P., Selle F., Ray-Coquard I., Provencher D., Prat Aparicio A., Vidal Boixader L., Scott C., Yunokawa M., Medioni J., Pecuchet N., Dubot C., De La Motte Rouge T., Kaminsky M. -C., Weber B., Lortholary A., Parkinson C., Ledermann J., Williams S., Banerjee S., Cosin J., Hoffman J., Plante M., Covens A., Sonke G., Joly F., Hirte H., Amit A., Matsumoto K., Tjulandin S., Hoon Kim J., Gladieff L., Sabbatini R., O'Malley D., Timmins P., Kredentser D., Lainez Milagro N., Barretina Ginesta M. P., Tibau Martorell A., Gomez De Liano Lista A., Ojeda Gonzalez B., Mileshkin L., Mandai M., Boere I., Ottevanger P., Nam J. -H., Filho E., Hamizi S., Cognetti F., Warshal D., Dickson-Michelson E., Kamelle S., McKenzie N., Rodriguez G., Armstrong D., Chalas E., Celano P., Behbakht K., Davidson S., Welch S., Helpman L., Fishman A., Bruchim I., Sikorska M., Slowinska A., Rogowski W., Bidzinski M., Spiewankiewicz B., Casado Herraez A., Mendiola Fernandez C., Gropp-Meier M., Saito T., Takehara K., Enomoto T., Watari H., Choi C. H., Kim B. -G., Weon Kim J., Hegg R., Poveda, A, Floquet, A, Ledermann, J, Asher, R, Penson, R, Oza, A, Korach, J, Huzarski, T, Pignata, S, Friedlander, M, Baldoni, A, Park-Simon, T, Tamura, K, Sonke, G, Lisyanskaya, A, Kim, J, Filho, E, Milenkova, T, Lowe, E, Rowe, P, Vergote, I, Pujade-Lauraine, E, Byrski, T, Pautier, P, Harter, P, Colombo, N, Scambia, G, Nicoletto, M, Nussey, F, Clamp, A, Poveda Velasco, A, Rodrigues, M, Lotz, J, Selle, F, Ray-Coquard, I, Provencher, D, Prat Aparicio, A, Vidal Boixader, L, Scott, C, Yunokawa, M, Medioni, J, Pecuchet, N, Dubot, C, De La Motte Rouge, T, Kaminsky, M, Weber, B, Lortholary, A, Parkinson, C, Williams, S, Banerjee, S, Cosin, J, Hoffman, J, Plante, M, Covens, A, Joly, F, Hirte, H, Amit, A, Matsumoto, K, Tjulandin, S, Hoon Kim, J, Gladieff, L, Sabbatini, R, O'Malley, D, Timmins, P, Kredentser, D, Lainez Milagro, N, Barretina Ginesta, M, Tibau Martorell, A, Gomez De Liano Lista, A, Ojeda Gonzalez, B, Mileshkin, L, Mandai, M, Boere, I, Ottevanger, P, Nam, J, Hamizi, S, Cognetti, F, Warshal, D, Dickson-Michelson, E, Kamelle, S, Mckenzie, N, Rodriguez, G, Armstrong, D, Chalas, E, Celano, P, Behbakht, K, Davidson, S, Welch, S, Helpman, L, Fishman, A, Bruchim, I, Sikorska, M, Slowinska, A, Rogowski, W, Bidzinski, M, Spiewankiewicz, B, Casado Herraez, A, Mendiola Fernandez, C, Gropp-Meier, M, Saito, T, Takehara, K, Enomoto, T, Watari, H, Choi, C, Kim, B, Weon Kim, J, Hegg, R, Poveda A., Floquet A., Ledermann J. A., Asher R., Penson R. T., Oza A. M., Korach J., Huzarski T., Pignata S., Friedlander M., Baldoni A., Park-Simon T. -W., Tamura K., Sonke G. S., Lisyanskaya A., Kim J. -H., Filho E. A., Milenkova T., Lowe E. S., Rowe P., Vergote I., Pujade-Lauraine E., Byrski T., Pautier P., Harter P., Colombo N., Scambia G., Nicoletto M., Nussey F., Clamp A., Penson R., Poveda Velasco A., Rodrigues M., Lotz J. -P., Selle F., Ray-Coquard I., Provencher D., Prat Aparicio A., Vidal Boixader L., Scott C., Yunokawa M., Medioni J., Pecuchet N., Dubot C., De La Motte Rouge T., Kaminsky M. -C., Weber B., Lortholary A., Parkinson C., Ledermann J., Williams S., Banerjee S., Cosin J., Hoffman J., Plante M., Covens A., Sonke G., Joly F., Hirte H., Amit A., Matsumoto K., Tjulandin S., Hoon Kim J., Gladieff L., Sabbatini R., O'Malley D., Timmins P., Kredentser D., Lainez Milagro N., Barretina Ginesta M. P., Tibau Martorell A., Gomez De Liano Lista A., Ojeda Gonzalez B., Mileshkin L., Mandai M., Boere I., Ottevanger P., Nam J. -H., Filho E., Hamizi S., Cognetti F., Warshal D., Dickson-Michelson E., Kamelle S., McKenzie N., Rodriguez G., Armstrong D., Chalas E., Celano P., Behbakht K., Davidson S., Welch S., Helpman L., Fishman A., Bruchim I., Sikorska M., Slowinska A., Rogowski W., Bidzinski M., Spiewankiewicz B., Casado Herraez A., Mendiola Fernandez C., Gropp-Meier M., Saito T., Takehara K., Enomoto T., Watari H., Choi C. H., Kim B. -G., Weon Kim J., and Hegg R.

Abstract

Background: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. The aim of this final analysis is to investigate the effect of olaparib on overall survival. Methods: This double-blind, randomised, placebo-controlled, phase 3 trial was done across 123 medical centres in 16 countries. Eligible patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status at baseline of 0–1, had histologically confirmed, relapsed, high-grade serous or high-grade endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, and had received two or more previous platinum regimens. Patients were randomly assigned (2:1) to receive olaparib tablets (300 mg in two 150 mg tablets twice daily) or matching placebo tablets using an interactive web or voice-response system. Stratification was by response to previous chemotherapy and length of platinum-free interval. Treatment assignment was masked to patients, treatment providers, and data assessors. The primary endpoint of progression-free survival has been reported previously. Overall survival was a key secondary endpoint and was analysed in all patients as randomly allocated. Safety was assessed in all patients who received at least one treatment dose. This trial is registered with ClinicalTrials.gov, NCT01874353, and is no longer recruiting patients. Findings: Between Sept 3, 2013 and Nov 21, 2014, 295 patients were enrolled. Patients were randomly assigned to receive either olaparib (n=196 [66%]) or placebo (n=99 [34%]). One patient, randomised in error, did not receive olaparib. Median follow-up was 65·7 months (IQR 63·6–69·3) with olaparib and 64·5 months (63·4–68·7) with placebo. Median overall survi

Published
2021

17. EPV132/#552 The prognostic impact of lower uterine segment involvement in women with low-risk endometrial carcinoma: a multicenter study

Author

Levin, G, primary, Brandt, B, additional, Helpman, L, additional, Eitan, R, additional, Vaknin, Z, additional, Lavie, O, additional, Ben Arie, A, additional, Amit, A, additional, Levy, T, additional, Namazov, A, additional, Ben Shachar, I, additional, Atlas, I, additional, Bruchim, I, additional, Perri, T, additional, and Gemer, O, additional

Published
2021
Full Text
View/download PDF

18. EPV131/#545 Lower uterine segment involvement in high-grade endometrial carcinoma is not independently associated with adverse oncological outcome

Author

Brandt, B, primary, Perri, T, additional, Helpman, L, additional, Eitan, R, additional, Vaknin, Z, additional, Lavie, O, additional, Ben Arie, A, additional, Amit, A, additional, Levy, T, additional, Namazov, A, additional, Ben Shachar, I, additional, Atlas, I, additional, Bruchim, I, additional, Levin, G, additional, and Gemer, O, additional

Published
2021
Full Text
View/download PDF

19. EPV133/#555 Minimally invasive approach in endometrial cancer with lower uterine segment involvement in ≥ stage ii: is it safe?

Author

Perri, T, primary, Kogan, L, additional, Helpman, L, additional, Eitan, R, additional, Vaknin, Z, additional, Lavie, O, additional, Ben Arie, A, additional, Amit, A, additional, Levy, T, additional, Namazov, A, additional, Ben Shachar, I, additional, Atlas, I, additional, Bruchim, I, additional, Levin, G, additional, and Gemer, O, additional

Published
2021
Full Text
View/download PDF

20. OP012/#257 Minimally invasive surgery is associated with an increased risk for local recurrence in high-grade endometrial carcinoma

Author

Levin, G, primary, Kogan, L, additional, Helpman, L, additional, Eitan, R, additional, Vaknin, Z, additional, Lavie, O, additional, Ben Arie, A, additional, Amit, A, additional, Levy, T, additional, Namazov, A, additional, Ben Shachar, I, additional, Atlas, I, additional, Bruchim, I, additional, Perri, T, additional, and Gemer, O, additional

Published
2021
Full Text
View/download PDF

22. Minimally Invasive Surgery in High-Grade Endometrial Carcinoma and Risk for Local Recurrence: An Israeli Gynecology Oncology Group Study

Author

Levin, G., primary, Kogan, L., additional, Helpman, L., additional, Eitan, R., additional, Vaknin, Z., additional, Lavie, O., additional, Ben-Arie, A., additional, Amit, A., additional, Levy, T., additional, Namazov, A., additional, ben Shachar, I., additional, Atlas, I., additional, Bruchim, I., additional, Perri, T., additional, and Gemer, O., additional

Published
2021
Full Text
View/download PDF

23. EPV136/#605 Metformin use among diabetic women and endometrial cancer survival: an Israeli gynecologic oncology group study

Author

Brandt, B, primary, Perri, T, additional, Helpman, L, additional, Eitan, R, additional, Vaknin, Z, additional, Lavie, O, additional, Ben Arie, A, additional, Amit, A, additional, Levy, T, additional, Namazov, A, additional, Ben Shachar, I, additional, Atlas, I, additional, Bruchim, I, additional, Kogan, L, additional, and Gemer, O, additional

Published
2021
Full Text
View/download PDF

24. O006/#340 Minimally invasive surgery in advanced endometrial carcinoma is associated with an increased risk for local recurrence

Author

Kogan, L, primary, Levin, G, additional, Helpman, L, additional, Eitan, R, additional, Vaknin, Z, additional, Lavie, O, additional, Ben Arie, A, additional, Amit, A, additional, Levy, T, additional, Namazov, A, additional, Ben Shachar, I, additional, Atlas, I, additional, Bruchim, I, additional, Brandt, B, additional, and Gemer, O, additional

Published
2021
Full Text
View/download PDF

25. Minimally Invasive Surgery in Advanced Endometrial Carcinoma Is Associated with an Increased Risk for Local Recurrence

Author

Kogan, L., primary, Levin, G., additional, Helpman, L., additional, Eitan, R., additional, Vaknin, Z., additional, Lavie, O., additional, Ben-Arie, A., additional, Amit, A., additional, Levy, T., additional, Namazov, A., additional, Ben Shachar, I., additional, Atlas, I., additional, Bruchim, I., additional, Brandt, B., additional, and Gemer, O., additional

Published
2021
Full Text
View/download PDF

26. LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial

Author

Gonzalez Martin, A., Rubio Perez, M.J., Heitz, F., Christensen, R.D., Colombo, N., Van Gorp, T., Oaknin, A., Leary, A., Gaba Garcia, L., Lebreton, C., De Sande González, L.M., Romeo Marin, M., Redondo, A., Barretina Ginesta, M.P., Perez Fidalgo, J.A., Santaballa Bertran, A., Bermejo-Pérez, M.J., Bruchim, I., Ray-Coquard, I.L., and Selle, F.

Published
2023
Full Text
View/download PDF

29. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Author

Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., Querleu, D., Banerjee, S., Blecharz, P., Bruchim, I., Cibula, D., Concin, N., Davidson, B., Devouassoux-Shisheboran, M., Ferrero, A., Glasspool, R., Gonzalez-Martin, A., Heinzelmann-Schwarz, V., Joly, F., Kim, J. W., Kridelka, F., Lorusso, D., Mahner, S., Mikami, M., Mirza, M. R., Nicum, S., O'Donnell, D. M., Pautier, P., Rodolakis, A., Sehouli, J., Selcukbiricik, F., Singh, N., Tan, D. S. P., Timmerman, D., Tognon, G., van der Velden, J., Witteveen, P. O., Zeimet, A. G., Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., Querleu, D., Banerjee, S., Blecharz, P., Bruchim, I., Cibula, D., Concin, N., Davidson, B., Devouassoux-Shisheboran, M., Ferrero, A., Glasspool, R., Gonzalez-Martin, A., Heinzelmann-Schwarz, V., Joly, F., Kim, J. W., Kridelka, F., Lorusso, D., Mahner, S., Mikami, M., Mirza, M. R., Nicum, S., O'Donnell, D. M., Pautier, P., Rodolakis, A., Sehouli, J., Selcukbiricik, F., Singh, N., Tan, D. S. P., Timmerman, D., Tognon, G., van der Velden, J., Witteveen, P. O., and Zeimet, A. G.

Published
2019

30. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Author

DDOD, Arts-assistenten Radiotherapie, MS Medische Oncologie, Cancer, Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., Querleu, D., Banerjee, S., Blecharz, P., Bruchim, I., Cibula, D., Concin, N., Davidson, B., Devouassoux-Shisheboran, M., Ferrero, A., Glasspool, R., Gonzalez-Martin, A., Heinzelmann-Schwarz, V., Joly, F., Kim, J. W., Kridelka, F., Lorusso, D., Mahner, S., Mikami, M., Mirza, M. R., Nicum, S., O'Donnell, D. M., Pautier, P., Rodolakis, A., Sehouli, J., Selcukbiricik, F., Singh, N., Tan, D. S. P., Timmerman, D., Tognon, G., van der Velden, J., Witteveen, P. O., Zeimet, A. G., DDOD, Arts-assistenten Radiotherapie, MS Medische Oncologie, Cancer, Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., Querleu, D., Banerjee, S., Blecharz, P., Bruchim, I., Cibula, D., Concin, N., Davidson, B., Devouassoux-Shisheboran, M., Ferrero, A., Glasspool, R., Gonzalez-Martin, A., Heinzelmann-Schwarz, V., Joly, F., Kim, J. W., Kridelka, F., Lorusso, D., Mahner, S., Mikami, M., Mirza, M. R., Nicum, S., O'Donnell, D. M., Pautier, P., Rodolakis, A., Sehouli, J., Selcukbiricik, F., Singh, N., Tan, D. S. P., Timmerman, D., Tognon, G., van der Velden, J., Witteveen, P. O., and Zeimet, A. G.

Published
2019

31. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Author

Selçukbiricik, Fatih, Colombo, N.; Sessa, C.; du Bois, A.; Ledermann, J.; McCluggage, W. G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; Baert, T.; Belaroussi, I.; Dashora, A.; Olbrecht, S.; Planchamp, F.; Querleu, D.; Baert, T.; Banerjee, S.; Belaroussi, I.; Blecharz, P.; Bruchim, I.; Cibula, D.; Colombo, N.; Concin, N.; Davidson, B.; Dashora, A.; Devouassoux-Shisheboran, M.; du Bois, A.; Ferrero, A.; Glasspool, R.; Gonzalez-Martin, A.; Heinzelmann-Schwarz, V.; Joly, F.; Kim, J. W.; Kridelka, F.; Ledermann, J.; Lorusso, D.; Mahner, S.; McCluggage, W. G.; McNeish, I.; Mikami, M.; Mirza, M. R.; Morice, P.; Nicum, S.; Olbrecht, S.; O'Donnell, D. M.; Pautier, P.; Planchamp, F.; Pignata, S.; Querleu, D.; Ray-Coquard, I.; Rodolakis, A.; Sehouli, J.; Selcukbiricik, F.; Sessa, C.; Singh, N.; Tan, D. S. P.; Timmerman, D.; Tognon, G.; van der Velden, J.; Vergote, I.; Witteveen, P. O.; Zeimet, A. G., Koç University Hospital, Selçukbiricik, Fatih, Colombo, N.; Sessa, C.; du Bois, A.; Ledermann, J.; McCluggage, W. G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; Baert, T.; Belaroussi, I.; Dashora, A.; Olbrecht, S.; Planchamp, F.; Querleu, D.; Baert, T.; Banerjee, S.; Belaroussi, I.; Blecharz, P.; Bruchim, I.; Cibula, D.; Colombo, N.; Concin, N.; Davidson, B.; Dashora, A.; Devouassoux-Shisheboran, M.; du Bois, A.; Ferrero, A.; Glasspool, R.; Gonzalez-Martin, A.; Heinzelmann-Schwarz, V.; Joly, F.; Kim, J. W.; Kridelka, F.; Ledermann, J.; Lorusso, D.; Mahner, S.; McCluggage, W. G.; McNeish, I.; Mikami, M.; Mirza, M. R.; Morice, P.; Nicum, S.; Olbrecht, S.; O'Donnell, D. M.; Pautier, P.; Planchamp, F.; Pignata, S.; Querleu, D.; Ray-Coquard, I.; Rodolakis, A.; Sehouli, J.; Selcukbiricik, F.; Sessa, C.; Singh, N.; Tan, D. S. P.; Timmerman, D.; Tognon, G.; van der Velden, J.; Vergote, I.; Witteveen, P. O.; Zeimet, A. G., and Koç University Hospital

Abstract

The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO-ESGO consensus conference on ovarian cancer was held on 12-14 April 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO-ESGO consensus conference, together with a summary of evidence supporting each recommendation., ESMO and ESGO funds

Published
2019

32. Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial

Author

Mirza, MR, primary, Dørum, A, additional, Benigno, B, additional, Mahner, S, additional, Bessette, P, additional, Bover Barcelo, IM, additional, Berton, D, additional, Ledermann, J, additional, Rimel, BJ, additional, Herrstedt, J, additional, Lau, S, additional, Canzler, U, additional, Palacio Vázquez, I, additional, Kalbacher, E, additional, Buscema, J, additional, Lorusso, D, additional, Debruyne, P, additional, Bruchim, I, additional, Guo, W, additional, Gupta, D, additional, de Jong, FA, additional, and Matulonis, UA, additional

Published
2019
Full Text
View/download PDF

34. Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 study

Author

González-Martín, A, primary, Pothuri, B, additional, Vergote, I, additional, Christensen, RD, additional, Graybill, W, additional, Mirza, MR, additional, McCormick, C, additional, Lorusso, D, additional, Hoskins, P, additional, Freyer, G, additional, Baumann, K, additional, Jardon, K, additional, Redondo, A, additional, Moore, RG, additional, Vulsteke, C, additional, O’Cearbhaill, RE, additional, Lund, B, additional, Backes, F, additional, Barretina-Ginesta, P, additional, Haggerty, AF, additional, Rubio-Pérez, MJ, additional, Shahin, MS, additional, Mangili, G, additional, Bradley, WH, additional, Bruchim, I, additional, Sun, K, additional, Malinowska, I, additional, Li, Y, additional, Gupta, D, additional, and Monk, BJ, additional

Published
2019
Full Text
View/download PDF

36. 71 The oncological safety of hysteroscopy in the diagnosis of early-stage endometrial cancer: an israel gynecologic oncology group study

Author

Volodarsky, M, primary, Namazov, A, additional, Gemer, O, additional, helpman, L, additional, Hag-Yahia, N, additional, Eitan, R, additional, Raban, O, additional, Vaknin, Z, additional, Leytes, S, additional, Lavie, O, additional, Amit, A, additional, Levy, T, additional, Ben Shachar, I, additional, Atlas, I, additional, Bruchim, I, additional, and Ben-Arie, A, additional

Published
2019
Full Text
View/download PDF

39. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Author

Colombo, N., primary, Sessa, C., additional, du Bois, A., additional, Ledermann, J., additional, McCluggage, W.G., additional, McNeish, I., additional, Morice, P., additional, Pignata, S., additional, Ray-Coquard, I., additional, Vergote, I., additional, Baert, T., additional, Belaroussi, I., additional, Dashora, A., additional, Olbrecht, S., additional, Planchamp, F., additional, Querleu, D., additional, Banerjee, S., additional, Blecharz, P., additional, Bruchim, I., additional, Cibula, D., additional, Colombo, N., additional, Concin, N., additional, Davidson, B., additional, Devouassoux-Shisheboran, M., additional, Ferrero, A., additional, Glasspool, R., additional, González-Martin, A., additional, Heinzelmann-Schwarz, V., additional, Joly, F., additional, Kim, J.W., additional, Kridelka, F., additional, Lorusso, D., additional, Mahner, S., additional, Mikami, M., additional, Mirza, M.R., additional, Nicum, S., additional, O’Donnell, D.M., additional, Pautier, P., additional, Rodolakis, A., additional, Sehouli, J., additional, Selcukbiricik, F., additional, Singh, N., additional, Tan, D.S.P., additional, Timmerman, D., additional, Tognon, G., additional, van der Velden, J., additional, Witteveen, P.O., additional, and Zeimet, A.G., additional

Published
2019
Full Text
View/download PDF

42. The european network for gynaecological oncological trial groups charta for privileged partnership

Author

Marth, C, Du Bois, A, Schauer, C, Casado, A, Vergote, I, Del Campo, J, Goudopoulou, A, Pujade Lauraine, E, Bruchim, I, Colombo, N, Pignata, S, Ledermann, J, Chekerov, R, Raza Mirza, M, Westermann, A, Glasspool, R, Taskiran, C, Fehr, M, Cibula, D, Cibula, D., COLOMBO, NICOLETTA, Marth, C, Du Bois, A, Schauer, C, Casado, A, Vergote, I, Del Campo, J, Goudopoulou, A, Pujade Lauraine, E, Bruchim, I, Colombo, N, Pignata, S, Ledermann, J, Chekerov, R, Raza Mirza, M, Westermann, A, Glasspool, R, Taskiran, C, Fehr, M, Cibula, D, Cibula, D., and COLOMBO, NICOLETTA

Published
2015

43. Successful response to docetaxel treatment in recurrent ovarian granulosa cell tumor: a case report

Author

Tal Shavit, Bruchim I, Ben-Harim Z, and Fishman A

Subjects
Ovarian Neoplasms, Humans, Antineoplastic Agents, Female, Taxoids, Docetaxel, Neoplasm Recurrence, Local, Aged, Granulosa Cell Tumor
Abstract

Ovarian granulosa cell tumor (GCT) is primarily treated surgically. Treatment for advanced or recurrent disease includes primary or adjuvant chemotherapy. Data about the efficacy of treatment with paclitaxel are limited, without data about the role of docetaxel in treating recurrent GCT.A 68-year-old patient with Stage IA ovarian GCT diagnosed ten years earlier, presented with a third episode of recurrent disease. Following the first event of recurrent disease, she underwent a second laparotomy followed by BEP chemotherapy. Because of new liver masses, she was treated with paclitaxel, with complete response. Following diagnosis of new liver lesions, third-line chemotherapy with docetaxel was initiated, resulting in stable disease and a PFI of 24 months.Docetaxel might be a good alternative for treating recurrent GCT.

Published
2012

44. Engot-Ov16/Nova: a Phase 3 Randomized Double-Blind Trial of Maintenance with Parp-Inhibitor Niraparib Versus Placebo in Patients with Platinum-Sensitive Ovarian Cancer

Author

Mirza, M.R., primary, Monk, B.J., additional, Ledermann, J.A., additional, Oza, A.M., additional, Del Campo, J.M., additional, Berek, J.S., additional, Mahner, S., additional, Wenham, R.M., additional, Vergote, I.B., additional, Fabbro, M., additional, Marth, C., additional, Dørum, A., additional, Lorusso, D., additional, Katsaros, D., additional, Bruchim, I., additional, Malander, S., additional, Herrstedt, J., additional, Agarwal, S., additional, Martell, R.E., additional, and Matulonis, U., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results